Publications found:
251,903
Sort by:
NAT Instrumentation: Operating Characteristics, Features and Selling Prices of Leading Analyzers
US$ 680.00
... synthesizers, thermal cyclers, robotic work-stations, and automated DNA probe analysis systems. The report reviews current instrumentation technologies and compares features of leading NAT analyzers marketed by Abbott, Beckman Coulter, BD, Bio-Rad, Gen-Probe, Tecan, Trinity Biotech and other manufacturers. ...
August 2011
20 pages
NAT Applications For Forensic, Paternity and Disease Susceptibility Testing
US$ 680.00
Global PDF: US$ 1,900.00 The report presents: Overview of the clinical significance and market needs for major forensic, paternity, disease susceptibility and other NAT applications. Extensive listings of companies developing and marketing NAT technologies and products. Contains 32 pages
August 2011
32 pages
Incontinence in Tunisia
US$ 900.00
... production and distribution plants within the country. Euromonitor International's Incontinence in Tunisia report offers a comprehensive guide to the size and shape ... data. Why buy this report? Get a detailed picture of the Incontinence market; Pinpoint growth sectors and identify factors driving change ...
August 2011
13 pages
Strategic Assessments of Leading North American Diagnostic Imaging Market Players
US$ 7,520.00
... updated and cost-effective information based on performance, capabilities, goals and strategies of the leading North American diagnostic imaging companies. To help current suppliers realistically assess their financial, technological and marketing capabilities vis-a-vis the leading competitors. To assist ...
August 2011
843 pages
Strategic Assessments of Leading European Diagnostic Imaging Market Players
US$ 7,760.00
... , annually updated and cost-effective information based on performance, capabilities, goals and strategies of the leading European diagnostic imaging companies. To help current suppliers realistically assess their financial, technological and marketing capabilities vis-a-vis the leading competitors. To ...
August 2011
850 pages
Strategic Assessments of Leading Japanese Diagnostic Imaging Market Players
US$ 7,600.00
... , annually updated and cost-effective information based on performance, capabilities, goals and strategies of the leading Japanese diagnostic imaging companies. To help current suppliers realistically assess their financial, technological and marketing capabilities vis-a-vis the leading competitors. To ...
August 2011
839 pages
Global Ultrasound Market: Strategic Assessments of Leading Suppliers
US$ 7,600.00
... effective information base on performance, capabilities, goals and strategies of the world’s leading ultrasound system suppliers. To help current suppliers realistically assess their financial, technological and marketing capabilities vis-a-vis the leading competitors. To assist potential market entrants in ...
August 2011
804 pages
Latest Product Innovations in Pet Care
US$ 2,000.00
... needs of consumers in mature and developing markets alike. Euromonitor International’s Latest Product Innovations in Pet Care global briefing offers an insight into the ... data. Why buy this report? Get a detailed picture of the Pet Care market; Pinpoint growth sectors and identify factors driving change; ...
August 2011
59 pages
Asthma and COPD Therapies: World Market 2011-2021
US$ 2,325.00
... charts and a research interview (shown in the accompanying lists). Asthma and COPD Therapies: World Market 2011-2021 shows you opportunities, challenges ... , France, UK, Spain, Italy, China and India Review R&D for asthma and COPD, assessing potential Investigate competition and opportunities influencing the ...
August 2011
138 pages
Companion Diagnostics: World Market Outlook 2011-2021
US$ 2,325.00
... both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers ... opinion to benefit your work. Why you should buy Companion Diagnostics: World Market Outlook 2011-2021 In this report, you will receive ...
August 2011
108 pages
Extremities Market Report: 2011 Edition
US$ 700.00
... for a major share. The present report analyzes the global extremity market. The US extremity market is also presented in the report. The report analyzes the major growth drivers ...
August 2011
40 pages
Global Atrial Fibrillation Market Report: 2011 Edition
US$ 700.00
... is particularly significant. The report provides an analysis of the global atrial fibrillation market. It also discusses major trends, growth drivers and developments in atrial fibrillation market. The report also presents the ...
August 2011
32 pages
Global Hepatitis C Virus (HCV) Market - An Analysis
US$ 800.00
... come due to increase in number of HCV positive drug addicts. This report titled “Global Hepatitis C Virus (HCV) Market– An Analysis” analyzes the various ... types, stages and incidences of HCV in different geographies. ...
August 2011
47 pages
Medical Imaging Market Report: 2011 Edition
US$ 800.00
... medical imaging market. The main competitors in the medical imaging market are GE, Siemens, Hitachi, Philips and Toshiba. This report delves into the regional analysis of medical imaging ... to pose threat to the global medical imaging market have been included. The report also profiles the major companies, with ...
August 2011
42 pages
The para-Amino Phenol Industry in China
US$ 7,448.00
... by the demand from the downstream products especially paracetamol, para-aminophenol (PAP) industry in China keeps developing in recent years. The output of PAP ... 2010 Introduction to PAP production methods Forecast on supply and demand of in China, 2011-2015 Besides, compared with the last edition finished ...
August 2011
59 pages
External Defibrillator market in India 2011
US$ 950.00
... description of the segments in the defibrillator market in India. The market overview section provides an insight into the market and highlights the market size and growth. Import ...
August 2011
32 pages
Competitor Analysis: Targeted Therapy of Hepatitis C
US$ 826.00
Product description The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online ...
August 2011
91 pages
Biomarkers: Market Research Report
US$ 4,800.00
... and Others (miRNA Analysis and Others). The total market is also analyzed by the following Application Areas: Biomarker Discovery, Clinical Drug Development, and ... , Inc., Rules-Based Medicine, Inc., and Siemens Healthcare Diagnostics, Inc. Market data and analytics are derived from primary and secondary ...
August 2011
1305 pages
Intravenous (IV) Solutions: Market Research Report
US$ 4,800.00
This report analyzes the worldwide markets for Intravenous (IV) Solutions in US$ Million. The report provides separate comprehensive analytics for the US, Canada ... ., Sino-Swed Pharmaceutical, Terumo Corporation, and Watson Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary ...
August 2011
274 pages
Overactive Bladder (OAB) Therapeutics: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Overactive Bladder (OAB) Therapeutics in US$ Million. The report provides separate comprehensive analytics for ... ., SALVAT Biotech, Sepracor Pharmaceuticals, Inc., and Watson Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary ...
August 2011
279 pages
Irritable Bowel Syndrome (IBS) Therapeutics: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Irritable Bowel Syndrome (IBS) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year ...
August 2011
433 pages
Stroke Prevention in Atrial Fibrillation - View on Upcoming Milestones
US$ 90.00
DETAILED DATA FROM ARISTOTLE STUDY AT ESC – AUGUST 28th. BMY is likely to announce detailed data on Eliquis in SPAF from the ARISTOTLE study. The data on Eliquis from ARISTOTLE will be compared to the data on Pradaxa from RELY trial and not Xarelto- ROCKET AF, as there are major differences in trial design. ...
August 2011
2 pages
Eisai - Catalysts Too Weak to Mitigate Key Patent Expiries
US$ 140.00
... Nov-10 and May-13 respectively); together they contributed ~56% of revenue in FY 03/11. Eisai solely depends on catalysts coming out of its pipeline. Following Halaven approval ... , Eisai has three late stage candidates E-2007/ perampanel ...
August 2011
8 pages
Roche, BMY - Zelboraf (Vemurafenib) approval- Competition to YERVOY starts
US$ 90.00
The USFDA approval of Zelboraf (Vemurafenib) for inoperable metastatic melanoma, well in advance of the PDUFA date is encouraging. USFDA has also approved the cobas BRAF mutation diagnostic test. This will reduce YERVOY uptake directly as ~50% of Metastatic Melanoma patients are B-RAF positive and Zelboraf ...
August 2011
2 pages
Gilead - Complera Approval - Positive Long Term Impact
US$ 90.00
Approval of Complera (GILD’s Truvada + Tibotec’s Edurant) reiterates GILD’s ... HIV infection. With the current economic turmoil, approval of once-daily Complera (formerly Fixed Dose Combination drug) impact may ... report released on 12th August, 2011, titled – “Complera Approval - Positive Long Term Impact”
August 2011
5 pages
Ranbaxy - When Will The Base Business Stabilize?
US$ 140.00
We reiterate our Market Perform rating on Ranbaxy after the Q2 CY11 result that was in line with our ... about a possible timely launch. Longer term potential of Ranbaxy seems promising with Daiichi-Ranbaxy likely to become the largest generic company in Japan ...
August 2011
6 pages
Cipla - Margin Improvement - A Healthy Sign.
US$ 140.00
... higher than our earnings estimate owing to the sharp improvement in gross margin. The improvement in gross margin (up by 330 bps, Y-o-Y) is largely due to the ... day exclusivity and (2) improvement in margin as contribution from Indore facility increases. For the longer term, CIPLA’s traditional business model ...
August 2011
6 pages
Celgene - Global Share Gains Continue + Pipeline Potential
US$ 140.00
... all commercial metrics – global share and duration gains, continued expansion of market ... access through approvals and reimbursements in the US and international market, and noteworthy operating efficiency places Celgene ... – “Global Share Gains Continue + Pipeline Potential”.
August 2011
6 pages
IPCA- Margin Improvement, Despite Lower Domestic Sales
US$ 140.00
... sales in WHO member countries. We expect several growth drivers for Ipca in the near term. (1) US generics growth even without the ... WHO member countries and branded formulations (3) margin improvement as sales mix improves in favor of formulation sales. We see Ipca as the best bet in the domestic formulations ...
August 2011
5 pages
TAKEDA - Multiple Challenges Blur Future!
US$ 140.00
There are three major concerns for Takeda – 1) Takeda has got European exposure by the Nycomed acquisition, but as both ... is expected. 2) Safety related issues with Actos affects market prospects of Takeda’s key candidate Aloglipin’s combination drug with Actos and, 3) Pipeline ...
August 2011
8 pages
China Freeze Drying System Industry Report, 2011 - 2012
US$ 1,600.00
With the rapid development of pharmaceutical industry in China, the market size of freeze drying equipment continuously expands, which reached RMB2.425 billion in 2009, including the market of cleanin...
July 2011
53 pages
U.S. Market for Surgical Gowns
US$ 3,995.00
... and patient from operative and post-operative infection. In the 1960s, surgical gowns became more specialized, incorporating an exhaust helmet system, which ... two companies in the United States—Stryker and Ecolab—provided such highly protective gowns and helmet systems to the U.S. market. Scope: This report ...
July 2011
56 pages
Dishman - Moving away from CRAMS
US$ 140.00
Dishman’s Q1 FY12 result was below our expectations ... Amcis. The standalone EBITDA increased largely driven by sales from disinfectants in India, supply of intermediate of Brilinta to Astra Zeneca and ... most of them (except for Brilinta intermediate supply) coming from its non-CRAM business. On CRAMs part, we see ...
July 2011
5 pages
Lupin - Impact of Thin Pipeline Showing Up
US$ 140.00
... reiterate our Underperform with target price of `360 on Lupin after its Q1FY12 result that reflected a reduction in ... fag end of the quarter impacted the overall performance. We have always remained concerned about Lupin’s thin US pipeline along with a ... higher depreciation to eat into the earnings of Lupin.
July 2011
8 pages
Global Protein Therapeutics Market Analysis
US$ 1,800.00
Single User PDF Format: US$ 1,800.00
Multi-User License: US$ 2,800.00
Hard Copy: US$ 2,200.00
CD-ROM: US$ 2,200.00 Within the global pharmaceutical industry, protein therapeutics has b...
July 2011
180 pages
